

POSTER PRESENTATION

Open Access

Vaccination with long NY-ESO-1 79-108 peptide and CpG-B leads to robust activation of CD4 and CD8 T cell responses in stage III/IV melanoma patients, and a new HLA-DR7 epitope

Petra Baumgartner¹, Carla Costa Nunes², Amélie Cachot², Hélène Maby-El Hajjami³, Laurène Cagnon⁴, Marion Braun⁵, Laurent Derré⁶, Jean-Paul Rivals⁷, Donata Rimoldi², Emanuela Romano⁴, Olivier Michielin⁸, Pedro Romero³, Camilla Jandus^{2*}, Daniel E Speiser³

From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) National Harbor, MD, USA. 4-8 November 2015

Although promising, the combination of long synthetic peptides and CpG-B oligodeoxynucleotides has not yet been tested as cancer vaccine. In this Phase I trial, 19 patients received a mean of 8 (range 1-12) monthly vaccines s.c. composed of the long synthetic NY-ESO79-108 peptide and CpG-B (PF-3512676), emulsified in Montanide ISA-51. In 18/18 evaluable patients, vaccination induced responses of both CD8 and CD4 T cells, starting early after initiation of immunotherapy and lasting for many months. The T cells responded antigenspecifically, with strong secretion of IFN γ and TNF α , irrespective of patient's HLAs. The most immunogenic region of the vaccine peptide was the NY-ESO-183-97 sequence, inducing HLA-DR or -DP restricted CD4 T cell responses in all patients tested. We discovered a novel and highly immunogenic epitope (HLA-DR7/NY-ESO-187-99); 5/5 HLA-DR7+ patients generated strong CD4 T cell responses, as detected directly ex-vivo with fluorescent multimers. Thus, vaccination with the long synthetic NY-ESO-179-108 peptide combined with the strong immune adjuvant CpG-B, a TLR-9 agonist, induced integrated, robust and functional CD8 and CD4 T cell responses in melanoma patients, supporting the further development of this immunotherapeutic approach.

¹Ludwig Center for Cancer Research at the University of Lausanne and Department of Oncology, University Hospital of Lausanne, Lausanne, Switzerland. ²Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland. ³Department of Oncology, Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland. ⁴Department of Oncology, University Hospital Center (CHUV), Lausanne, Switzerland. ⁵Miltenyi Biotech GmbH, Bergisch Galdbach, Germany. ⁶Urology Research Unit, Urology Department, University Hospital Center (CHUV), Lausanne, Switzerland. ⁷Department of Otolaryngology, Head and Neck Surgery, University Hospital Center (CHUV), Lausanne, Switzerland. ⁸Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

Published: 4 November 2015

doi:10.1186/2051-1426-3-S2-P437

Cite this article as: Baumgartner et al.: Vaccination with long NY-ESO-1 79-108 peptide and CpG-B leads to robust activation of CD4 and CD8 T cell responses in stage III/IV melanoma patients, and a new HLA-DR7 epitope. Journal for ImmunoTherapy of Cancer 2015 3(Suppl 2):P437.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit



Full list of author information is available at the end of the article



Authors' details

²Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland